Aurion Biotech’s mission is to restore vision to millions of patients with life-changing regenerative therapies. We received the prestigious Prix Galien award for best start-up in biotech.
Our lead candidate is for treatment of corneal edema secondary to corneal endothelial disease – the first clinically validated cell therapy for corneal care. We received regulatory approval in Japan and are initiating clinical trials in the U.S. Aurion’s investors are: Deerfield, Alcon, Petrichor, Flying L Partners, Falcon Vision / KKR, and Visionary Ventures.
